PD-1
11 drugs Oncology
16
approved indications
11
Approved Drugs
8
Companies
31
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (8 companies)
✓ All 11 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (31 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Bristol-Myers Squibb 3 drugs
Merck 2 drugs
Regeneron 1 drug
By Therapeutic Area
Oncology 6 drugs
Other 5 drugs
Drugs by Company PRO
Bristol-Myers Squibb 3 drugs
Merck 2 drugs
Regeneron 1 drug
BEIGENE 1 drug
GSK 1 drug
INCYTE CORP 1 drug
AKESO BIOPHARMA 1 drug
COHERUS BIOSCIENCES INC 1 drug
By Therapeutic Area
Oncology 6 drugs
KEYTRUDA, OPDIVO, TEVIMBRA, OPDIVO QVANTIG +2 more
Other 5 drugs
LIBTAYO, OPDUALAG, ZYNYZ, PENPULIMAB-KCQX +1 more
Indications Treated
Esophageal CancerEsophageal Squamous Cell CarcinomaGastric CancerGastroesophageal Junction AdenocarcinomaUnresectable melanomaMetastatic melanomaRenal Cell CarcinomaMelanomaNon-Small Cell Lung CancerClassical Hodgkin LymphomaHead and Neck CancerUrothelial CarcinomaColorectal CancerHepatocellular CarcinomaMesotheliomaEndometrial CancerSolid TumorsNasopharyngeal CarcinomaCervical CancerMerkel Cell CarcinomaCutaneous Squamous Cell CarcinomaTriple-Negative Breast CancerBiliary Tract CancerSquamous Cell Carcinoma of the Anal CanalMetastatic cutaneous squamous cell carcinomaLocally advanced cutaneous squamous cell carcinomaAdjuvant treatment of cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiationLocally advanced basal cell carcinomaMetastatic basal cell carcinomaFirst-line treatment of locally advanced or metastatic non-small cell lung cancer in combination with platinum-based chemotherapy + 1 more
All Drugs Targeting PD-1
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| KEYTRUDA Top | Merck | 2014 | 16 | Oncology |
| OPDIVO Top | Bristol-Myers Squibb | 2014 | 11 | Oncology |
| LIBTAYO Top | Regeneron | 2018 | 7 | |
| TEVIMBRA | BEIGENE | 2024 | 4 | Oncology |
| OPDIVO QVANTIG | Bristol-Myers Squibb | 2024 | 3 | Oncology |
| OPDUALAG | Bristol-Myers Squibb | 2022 | 2 | |
| JEMPERLI | GSK | 2021 | 2 | Oncology |
| ZYNYZ | INCYTE CORP | 2023 | 2 | |
| KEYTRUDA QLEX | Merck | 2025 | 2 | Oncology |
| PENPULIMAB-KCQX | AKESO BIOPHARMA | 2025 | 1 | |
| LOQTORZI | COHERUS BIOSCIENCES INC | 2023 | 1 |